Clin2
NCT07621640Possibly a fitNot yet recruiting

Brown Fat and Weight Loss Response to Semaglutide

ObesityMetabolic SyndromeBrown Adipose Tissue

Treatments studied

Part of Hormones & metabolism clinical trials.

This study investigates how brown adipose tissue (a special type of fat that burns calories) affects how well semaglutide (Wegovy) works for weight loss. You'll undergo imaging and blood tests while starting semaglutide to help researchers understand individual differences in treatment response.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
20 years to 70 years
Study type
Interventional

Who can take part

  • Age 20–70 years old
  • Just starting semaglutide (Wegovy) treatment for the first time
  • BMI of 27 or higher AND at least one weight-related health condition (high blood pressure, high cholesterol, fatty liver, sleep apnea, heart disease, or joint pain), OR BMI of 30 or higher
  • No type 1 or type 2 diabetes diagnosis
  • No recent neck surgery, radiation to the neck, or beta-blocker medications
  • No family history of medullary thyroid cancer or MEN2 syndrome, and able to safely undergo MRI scans

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05419726Recruiting
Semaglutide study to see how brown fat responds in weight loss

This trial studies how brown fat (a type of body fat) changes after starting semaglutide for weight loss. You may help researchers understand how this medication affects the body’s energy use, which could improve weight-loss treatments.

Los Angeles, California
NCT06825793Not yet recruiting
Semaglutide for weight loss in obesity

This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.

NCT06633783Not yet recruiting· Phase 3
Semaglutide injection for weight loss study

This study tests an injectable medication called semaglutide to help with weight loss in people with a BMI of 28 or higher who have struggled to lose weight before. It compares the study drug to a similar approved weight loss medicine (Wegovy).

Xuancheng, Anhui
NCT05340868Recruiting
Study body response to oral semaglutide in overweight adults

This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.

Bialystok, Podlaskie Voivodeship
NCT06738979Not yet recruiting· Phase 3
Comparing semaglutide injection to Wegovy® for weight loss

This study tests a new injectable medication (semaglutide) compared to the approved drug Wegovy® for weight loss in people with obesity. It may help you lose weight if you have struggled to keep weight off with diet alone.

Hefei, Anhui
NCT07323134Not yet recruiting
Semaglutide for obesity and gut health

This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.